Human Leukocyte Antigen (HLA) Typing for Oncology Immunotherapy Global Market Report 2026

The human leukocyte antigen (HLA) typing for oncology immunotherapy market size has grown strongly in recent years. It will grow from $1.22 billion in 2025 to $1.31 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing prevalence of cancer globally, advancement of PCR and sequencing technologies, rising adoption of precision oncology approaches, growth in clinical research for immunotherapies, expanding use of biomarker driven treatment selection.

The human leukocyte antigen (HLA) typing for oncology immunotherapy market size is expected to see strong growth in the next few years. It will grow to $1.79 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growing pipeline of cell and gene therapies, increasing investment in personalized immunotherapy research, rising demand for companion diagnostics, expansion of oncology clinical trials worldwide, increasing regulatory support for precision medicine. Major trends in the forecast period include increasing adoption of next generation sequencing based hla typing, rising integration of hla profiling in adoptive t cell therapies, growing use of high resolution hla typing in clinical trials, expansion of personalized cancer vaccine development, rising focus on predictive immune compatibility testing.

The increasing adoption of personalized medicine is projected to propel the growth of the human leukocyte antigen (HLA) typing for oncology immunotherapy market in the coming years. Personalized medicine involves customizing medical treatments and healthcare decisions based on an individual’s genetic, molecular, and clinical characteristics to achieve more precise and effective therapy. The rise in personalized medicine is driven by advancements in genomics, which enable clinicians to detect genetic variations affecting disease susceptibility and drug response, allowing for more targeted and efficacious treatments. Human leukocyte antigen typing facilitates personalized oncology immunotherapy by determining a patient’s distinct immune profile, which helps tailor treatments to optimize tumor antigen recognition and immune response. For instance, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, up from 6 in 2022, including 7 newly approved cancer drugs and 3 for other diseases and conditions. Therefore, the increasing adoption of personalized medicine is driving the growth of the human leukocyte antigen (HLA) typing for oncology immunotherapy market.

Key companies operating in the human leukocyte antigen (HLA) typing for oncology immunotherapy market are focusing on developing innovative solutions such as allele-specific patient selection to enhance personalized immunotherapy efficacy and improve clinical outcomes. Allele-specific patient selection involves identifying patients based on their specific HLA gene variants to tailor immunotherapy for optimal effectiveness. For example, in August 2024, Thermo Fisher Scientific Inc., a US-based biotechnology company, received FDA approval for the SeCore HLA typing kit for use as a companion diagnostic with a T-cell receptor therapy for synovial sarcoma. This approval expands HLA sequencing from transplant diagnostics into oncology immunotherapy by enabling precise patient selection for TCR-based treatments targeting tumor antigens.

In November 2023, Genome Diagnostics B.V., a Netherlands-based molecular diagnostics company, partnered with OSE Immunotherapeutics SA to create an HLA A02 companion diagnostic for cancer patients. Through this collaboration, the companies aim to develop and validate an NGS-based companion diagnostic test for HLA-A02 typing to identify NSCLC patients eligible for OSE's Tedopi cancer vaccine in its Phase 3 trial. OSE Immunotherapeutics SA is a France-based clinical-stage biotechnology company focused on developing first-in-class, next-generation immuno-oncology and immuno-inflammation therapies.

Major companies operating in the human leukocyte antigen (HLA) typing for oncology immunotherapy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson Company, Eurofins Scientific SE, Illumina Inc., Werfen, QIAGEN N.V., Versiti Inc., CareDx Inc., Oxford Nanopore Technologies Plc., Pacific Biosciences of California Inc., Takara Bio Inc., HistoGenetics LLC, Biofortuna Limited, Bio‑Rad Laboratories Inc., DKMS Life Science Lab, ClinImmune Inc., BGI Genomics Co. Ltd., Immudex A/S, ProImmune Ltd.

North America was the largest region in the human leukocyte antigen (HLA) typing for oncology immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human leukocyte antigen (HLA) typing for oncology immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human leukocyte antigen (HLA) typing for oncology immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human leukocyte antigen (HLA) typing for oncology immunotherapy market consists of revenues earned by entities by providing services such as tissue and organ matching, immunotherapy response prediction, and personalized therapy planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The human leukocyte antigen (HLA) typing for oncology immunotherapy market also includes sales of multiplex detection systems, real-time polymerase chain reaction (PCR) thermal cyclers, and standard PCR thermal cyclers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human leukocyte antigen (HLA) typing for oncology immunotherapy is a genetic testing method that determines a patient’s HLA profile, which controls immune system recognition of cells. It guides personalized cancer immunotherapies, including adoptive T-cell therapies or cancer vaccines, by aligning treatments with the patient’s immune compatibility. This testing helps predict therapeutic efficacy, reduce immune-related adverse effects, and optimize outcomes in precision oncology.

The key technologies of human leukocyte antigen (HLA) typing for oncology immunotherapy include polymerase chain reaction (PCR)-based, sequencing-based, sequence-specific oligonucleotide (SSO), sequence-specific primer (SSP), and others. PCR-based techniques amplify specific DNA sequences for detection, analysis, or research purposes. Product types include reagents and kits, instruments, and software. Applications include cancer diagnosis, personalized medicine, research, clinical trials, and others, serving hospitals and diagnostic laboratories, research institutes, academic centers, pharmaceutical and biotechnology companies, and other end-users.

Tariffs on imported sequencing instruments, PCR reagents, diagnostic kits, and laboratory equipment are impacting the HLA typing for oncology immunotherapy market by increasing operational and procurement costs, particularly affecting sequencing-based and high-resolution typing technologies. Regions such as North America, Europe, and Asia-Pacific that rely on cross-border supply chains for genomic instruments and reagents are most affected. Hospitals, diagnostic laboratories, and biotechnology companies may face higher testing costs, potentially influencing research budgets and therapy pricing. However, tariffs are also encouraging domestic production of molecular diagnostics reagents and localized manufacturing of sequencing platforms, strengthening regional supply chains and fostering innovation in cost-effective HLA typing solutions.

The human leukocyte antigen (HLA) typing for oncology immunotherapy market research report is one of a series of new reports that provides human leukocyte antigen (HLA) typing for oncology immunotherapy market statistics, including human leukocyte antigen (HLA) typing for oncology immunotherapy industry global market size, regional shares, competitors with a human leukocyte antigen (HLA) typing for oncology immunotherapy market share, detailed human leukocyte antigen (HLA) typing for oncology immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the human leukocyte antigen (HLA) typing for oncology immunotherapy industry. This human leukocyte antigen (HLA) typing for oncology immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.